Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07872644
NA

Safety in Ovarian Cancer for Average-Risk Women - Analysis

Sponsor: Mercy BioAnalytics, Inc.

View on ClinicalTrials.gov

Summary

This study is designed to evaluate the safety, specificity, and downstream diagnostic burden of the Evident™ Ovarian Cancer Screening Test in average-risk postmenopausal women. Participants will provide a blood sample for screening and will be followed for approximately 12 months to assess test safety, specificity, downstream diagnostic procedures, and ovarian cancer outcomes.

Official title: SOARA: Safety in Ovarian Cancer for Average-Risk Women - Analysis Clinical Validation Protocol

Key Details

Gender

FEMALE

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1750

Start Date

2026-11

Completion Date

2028-05

Last Updated

2026-10-13

Healthy Volunteers

Yes

Conditions

Interventions

DIAGNOSTIC_TEST

Blood-Based Ovarian Cancer Screening Test

A blood sample will be collected and analyzed using an investigational blood-based ovarian cancer screening test. Participants with positive screening results will be advised to undergo follow-up transvaginal ultrasound (TVUS) and may elect repeat blood-based testing. Additional clinical evaluation is determined by their healthcare provider.

Locations (2)

Mercy BioAnalytics, Inc.

Waltham, Massachusetts, United States

83Bar

Austin, Texas, United States